PubRank

Mario Scartozzi

Author PubWeight™ 30.89‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 PTEN expression and KRAS mutations on primary tumors and metastases in the prediction of benefit from cetuximab plus irinotecan for patients with metastatic colorectal cancer. J Clin Oncol 2009 3.48
2 Cetuximab plus gemcitabine and cisplatin compared with gemcitabine and cisplatin alone in patients with advanced pancreatic cancer: a randomised, multicentre, phase II trial. Lancet Oncol 2008 2.40
3 The response of breast cancer cells to mesenchymal stem cells: a possible role of inflammation by breast implants. Plast Reconstr Surg 2013 1.39
4 Evolving strategies for the treatment of hepatocellular carcinoma: from clinical-guided to molecularly-tailored therapeutic options. Cancer Treat Rev 2010 1.24
5 Pancreatic cancer: progress in cancer therapy. Crit Rev Oncol Hematol 2008 1.04
6 The challenge of targeted therapies for gastric cancer patients: the beginning of a long journey. Expert Opin Investig Drugs 2014 0.98
7 Molecular biomarkers of resistance to anti-EGFR treatment in metastatic colorectal cancer, from classical to innovation. Crit Rev Oncol Hematol 2013 0.93
8 Basal and bevacizumab-based therapy-induced changes of lactate dehydrogenases and fibrinogen levels and clinical outcome of previously untreated metastatic colorectal cancer patients: a multicentric retrospective analysis. Expert Opin Biol Ther 2014 0.89
9 Cancer stem cell gene profile as predictor of relapse in high risk stage II and stage III, radically resected colon cancer patients. PLoS One 2013 0.88
10 Clinical evidence for three distinct gastric cancer subtypes: time for a new approach. PLoS One 2013 0.88
11 Profiling tumor-associated markers for early detection of malignant mesothelioma: an epidemiologic study. Cancer Epidemiol Biomarkers Prev 2008 0.87
12 Biliary tract cancers: molecular profiling as a tool for treatment decisions. A literature review. Cancer Treat Rev 2006 0.85
13 Prognostic role of interleukin-1beta gene and interleukin-1 receptor antagonist gene polymorphisms in patients with advanced gastric cancer. J Clin Oncol 2005 0.85
14 COX-2 and NF-KB overexpression is common in pancreatic cancer but does not predict for COX-2 inhibitors activity in combination with gemcitabine and oxaliplatin. Am J Clin Oncol 2007 0.85
15 Gastric cancer treatment: a systematic review. Oncol Rep 2004 0.84
16 Locally advanced rectal cancer: from molecular profiling to clinical practice. A literature review: Part 2. Expert Opin Pharmacother 2009 0.84
17 Epidermal growth factor receptor status in stages of resected non-small cell lung cancer: implications for treatment with epidermal growth factor receptor inhibitors. Anal Quant Cytol Histol 2011 0.82
18 Predictive and prognostic role of E-cadherin protein expression in patients with advanced gastric carcinomas treated with palliative chemotherapy. Tumour Biol 2004 0.82
19 Adjuvant chemotherapy in gastric cancer. The Italian experience and review of the literature. Suppl Tumori 2003 0.82
20 Multidisciplinary treatment of locally advanced rectal cancer: a literature review. Part 1. Expert Opin Pharmacother 2009 0.81
21 Thymidylate synthase, topoisomerase-1 and microsatellite instability: relationship with outcome in mucinous colorectal cancer treated with fluorouracil. Anticancer Res 2013 0.79
22 A cost-benefit analysis of chemotherapy for gastric cancer. Expert Opin Pharmacother 2004 0.78
23 Molecular biology for stage II colorectal cancer: the jury is still out. J Clin Oncol 2007 0.78
24 Pathophysiology of cardiotoxicity induced by nonanthracycline chemotherapy. J Cardiovasc Med (Hagerstown) 2016 0.77
25 Panitumumab: the evidence for its use in the treatment of metastatic colorectal cancer. Core Evid 2010 0.77
26 Pharmacogenomics of cetuximab in metastatic colorectal carcinoma. Pharmacogenomics 2014 0.77
27 Pegylated liposomal doxorubicin, 5-fluorouracil and cisplatin versus mitomycin-C, 5-fluorouracil and cisplatin for advanced gastric cancer: a randomized phase II trial. Cancer Chemother Pharmacol 2010 0.77
28 Women and lung cancer: clinical and molecular profiling as a determinate for treatment decisions: a literature review. Crit Rev Oncol Hematol 2008 0.77
29 Prognostic Value for Incidental Antihypertensive Therapy With β-Blockers in Metastatic Colorectal Cancer. Medicine (Baltimore) 2015 0.77
30 Elderly patients with advanced colorectal cancer: tolerability and activity of chemotherapy. Tumori 2006 0.77
31 Recent aspects of sunitinib therapy in patients with metastatic clear-cell renal cell carcinoma: a systematic review of the literature. Curr Urol Rep 2015 0.77
32 VEGF expression and response to sunitinib in patients with metastatic clear cell renal cell carcinoma. Anticancer Res 2013 0.76
33 Chemotherapy-free intervals in patients with metastatic colorectal cancer: a tale of two cities? J Clin Oncol 2010 0.75
34 Locally advanced rectal cancer patients receiving radio-chemotherapy: a novel clinical-pathologic score correlates with global outcome. Int J Radiat Oncol Biol Phys 2009 0.75
35 The Tower of Babel of liver metastases from colorectal cancer: are we ready for one language? Crit Rev Oncol Hematol 2012 0.75
36 Doses of capecitabine and oral vinorelbine are not relevant for efficacy in breast cancer patients: an analysis of dose intensity. Tumori 2011 0.75
37 Selected news from the 2014 Genitourinary Cancers Symposium: translating novel strategies into clinical practice. Future Oncol 2014 0.75
38 Role and mechanisms of resistance of epidermal growth factor receptor antagonists in the treatment of colorectal cancer. Expert Opin Investig Drugs 2015 0.75
39 Perspectives from American Society of Clinical Oncology: translational and clinical research highlights in breast and colorectal cancers. Future Oncol 2014 0.75
40 Adenocarcinoma arising from ileoanal J-pouch mucosa: an announced event? Inflamm Bowel Dis 2011 0.75
41 Angiogenetic pathway as a therapeutic target in renal cell carcinoma. Anal Quant Cytol Histol 2012 0.75
42 Translational challenges from the 2014 Gastrointestinal Cancers Symposium: toward a true tailored therapy through effective research. Future Oncol 2014 0.75
43 Second-line chemotherapy with irinotecan, 5-fluorouracil and leucovorin (FOLFIRI) in relapsed or metastatic gastric cancer: lessons from clinical practice. Tumori 2011 0.75
44 Pathophysiology of cardiotoxicity induced by nonanthracycline chemotherapy. J Cardiovasc Med (Hagerstown) 2016 0.75
45 New frontiers in the neoadjuvant therapy of pancreatic adenocarcinoma: apart from therapeutical protocols. JOP 2005 0.75
46 Predictive factors for sunitinib treatment response in advanced renal cell carcinoma: are we really making steps forward? Anal Quant Cytopathol Histpathol 2015 0.75
47 [Non-small cell lung carcinoma: pathology, biology and prognosis]. Suppl Tumori 2004 0.75